Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML

By sjmartinez • June 29, 2023

Pratz KW, Cherry M, Altman JK, Cooper BW, Podoltsev NA, Cruz JC, Lin TL, Schiller GJ, Jurcic JG, Asch A, Wu R, Hill JE, Gill SC, James AJ, Rich ES, Hasabou N, Perl AE, Levis MJ. Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. J Clin Oncol. 2023 Jun 28:JCO2202721. doi: 10.1200/JCO.22.02721. Epub ahead of print. PMID: 37379495.

Tags: Hematology/Oncology, Publications

Glucarpidase for Treatment of High-Dose Methotrexate Toxicity

Gupta S, Kaunfer SA, Chen KL, Dias JA, Vijayan A, Rajasekaran A, Prosek J, Truong HL, Wood A, Bassil C, Renaghan AD, Shah CV, Zhang[...]

Warm Autoimmune Hemolytic Anemia as a Rare Presentation of Pre-fibrotic Primary Myelofibrosis

Lai SY, Lo AE, Wu P. Warm Autoimmune Hemolytic Anemia as a Rare Presentation of Pre-fibrotic Primary Myelofibrosis. Cureus. 2024 Dec 5;16(12):e75155. doi: 10.7759/cureus.75155. PMID:[...]

Case report: High-grade serous tubo-ovarian carcinoma with FGFR2::IQCG fusion and insights into targetability

Sono R, Konecny GE, Zhang L. Case report: High-grade serous tubo-ovarian carcinoma with FGFR2::IQCG fusion and insights into targetability. Front Oncol. 2024 Dec 20;14:1514471. doi: 10.3389/fonc.2024.1514471. PMID:[...]